logo
logo

Geneos Therapeutics Secures $17 Million In Series A2 Financing To Advance Personalized Cancer Immunotherapy Platform

Mar 24, 2022•over 3 years ago

Amount Raised

$17 Million

Round Type

series a

Description

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of tumor neoantigen targeted personalized immunotherapies, announced today that it has secured $17 million in Series A2 financing. The financing was led by Flerie Invest with participation from all existing Series A investors including Santé Ventures, Korea Investment Partners (KIP) – Global Bio Fund, and INOVIO Pharmaceuticals, Inc. (NASDAQ: INO). In conjunction with the financing, Dr

Company Information

Company

Geneos Therapeutics

About

At Geneos Therapeutics, we believe that personalized therapies are the future of cancer treatment. Our passion is to develop personalized therapies to unleash the most powerful force against cancer – patients' own immune system. Our approach using our GT-EPICTM platform is to target unique neoantigens (abnormal mutations produced by cancer cells) from individual patient tumors to develop novel and personalized treatments for cancer. We have an experienced management team with a track record of success in building immunotherapy-based companies.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech